Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-332-3241
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics Inc (NASDAQ:AXSM) posted its earnings results on Thursday, March, 14th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
6 brokers have issued 1-year price objectives for Axsome Therapeutics' shares. Their forecasts range from $23.00 to $45.00. On average, they anticipate Axsome Therapeutics' stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 75.7% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.
What is the consensus analysts' recommendation for Axsome Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.
What are Wall Street analysts saying about Axsome Therapeutics stock?
Here are some recent quotes from research analysts about Axsome Therapeutics stock:
- 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (4/19/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $25 PT on AXSM. Axsome pursues new indications for drugs approved in other indications, sometimes using new combinations or new routes of administration. We see this as a relatively balanced risk strategy and view the pipeline as robust, with trials spanning CNS and pain indications. We particularly value AXS-05 and its applicability to neuropsychiatric indications where we feel the individual compounds dextromethorphan (DM) and bupropion (BP) are derisked through proven efficacy in related indications." (3/21/2019)
- 3. HC Wainwright analysts commented, "We utilize a risk-adjusted net present value (rNPV) approach to assessing Axsome shares. We apply a 20% discount rate to all future cash flows along with a 28.1% effective tax rate and 33% sales and marketing rate. The probabilities of approval for all of Axsome’s candidates currently range from 10% to 30%." (1/31/2019)
Has Axsome Therapeutics been receiving favorable news coverage?
Media stories about AXSM stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include Uniqure (QURE), Nabriva Therapeutics (NBRV), Endocyte (ECYT), AnaptysBio (ANAB), Myokardia (MYOK), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Xencor (XNCR), Arrowhead Pharmaceuticals (ARWR), Ironwood Pharmaceuticals (IRWD), Zai Lab (ZLAB), Enanta Pharmaceuticals (ENTA), Allakos (ALLK), Madrigal Pharmaceuticals (MDGL) and Endo International (ENDP).
What other stocks do shareholders of Axsome Therapeutics own?
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
- Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
- Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
- Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
- Joseph Debrah-Afful, Director of Fin.
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Who are Axsome Therapeutics' major shareholders?
Axsome Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.07%). Company insiders that own Axsome Therapeutics stock include Mark Coleman and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.
Which major investors are buying Axsome Therapeutics stock?
AXSM stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $15.94.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $530.48 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
What is Axsome Therapeutics' official website?
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
